ALSO NOTED: Hollis-Eden shelves radiation treatment; Abeille and SymBio ink pact; and much more...

> Hollis-Eden has decided to shelve its radiation sickness drug Neumune after it was rejected by the HHS. Report

> Abeille Pharmaceuticals and SymBio Pharmaceuticals have signed a development and commercialization pact for AB-1001--Abeille's transdermal patch for chemotherapy-induced nausea and vomiting. The agreement covers Japan, China, Korea, Taiwan and Singapore. Abeille stands to earn up to $21 million in upfront fees and milestones. AB-1001 is slated to begin a Phase III trial in the second quarter as researchers study its ability to deliver the 5HT3-antagonist through the skin. Release

> Analysts are nervously awaiting clinical trial data for AGI-1067, saying that it is widely expected to fail a key study. If they're wrong, though, AstraZeneca could see its stock rise sharply. AstraZeneca agreed to pay up to a billion dollars for the licensing rights to the drug, which is being developed by AtheroGenics. Report

> The FDA has informed Endo and Vernalis that it will need an additional three months to review Endo's sNDA for Frova. Release

> MedImmune will lease a portion of the HGS headquarters facility located in Rockville, MD, for the development and manufacturing of clinical trial material for cell culture-based seasonal and pandemic influenza vaccine. Release 

> Roche is returning rights to IP regarding HIV fusion inhibitor peptides to Trimeris. Report

> Emergent BioSolutions has forged a licensing deal with Coley Pharmaceutical to use VaxImmune to develop new anthrax vaccines. Report

> Hit by increased competition from generic drugs, Sanofi-Aventis says it will cut 200 manufacturing jobs in Ireland. Report

> France's Sanofi-Aventis is rolling out its disposable insulin pen in Europe next month. Report

And Finally… A new report on China's pharma industry says that new efforts to bolster R&D work there are designed to propel the country to the top ranks of global pharma leaders. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.